Anti-Obesity Drugs Market - Global Forecast 2026-2032

The anti-obesity drugs market is evolving rapidly, shaped by new clinical advances, increased demand across care settings, and heightened regulatory expectations. Senior leaders in pharmaceutical, clinical, and payer organizations must navigate complex commercialization pathways and adapt to changing patient and supply needs. Early, strategic insights are essential for building long-term value in this market.

Market Snapshot: Anti-Obesity Drugs Market

The anti-obesity drugs market achieved notable expansion from USD 4.38 billion in 2025 to USD 4.67 billion in 2026 and is projected to reach USD 7.07 billion by 2032, growing at a CAGR of 7.07%. This growth trajectory is fueled by continual clinical innovation, broader integration of novel therapies, and expanding demand that now encompasses both clinical and home-based care settings. Competitive momentum is increasing, and stakeholders are recognizing the need to align their market approach with evolving therapeutic adoption and distribution models.

Scope & Segmentation

Product Types: GLP-1 Agonists, Naltrexone Bupropion, Orlistat, Phentermine Topiramate, and SGLT2 Inhibitors. Each therapy class brings distinct efficacy profiles, informing product positioning and tailoring to diverse patient needs as required by guidelines and real-world scenarios.
Dosage Forms: Capsules, Injectables (including Prefilled Pens and Vials), and Tablets. The selected dosage form impacts patient adherence, workflow integration, and logistics for clinical and homecare environments.
Routes of Administration: Injectable (Autoinjectors, Prefilled Pens, Vials), Nasal, and Oral. Route of administration influences device design, workflow efficiencies, and training for care providers and patients.
End User Channels: Clinics, Homecare Settings, Hospitals. Different procurement processes and onboarding requirements affect patient pathways and ongoing management support across each channel.
Geographic Regions: The Americas, Europe Middle East & Africa, and Asia-Pacific. Regional distinctions in regulation, infrastructure, and reimbursement drive nuanced strategies for market access and channel development.

Key Takeaways

New therapies with advanced efficacy are prompting updates to clinical protocols, compelling decision-makers to routinely review titration, monitoring, and management strategies in care delivery.
Prefilled pens and autoinjectors are increasing adoption outside established clinical venues, improving patient autonomy and enabling homecare expansion.
Integrated care pathways now demand coordinated work between endocrinologists, primary care providers, and allied health professionals, with digital tools and remote monitoring improving patient outcomes and compliance.
Payer strategies focus on outcomes-based contracts and real-world evidence, influencing reimbursement, preferred placement, and product access across all market segments.
Understanding the full range of products, delivery technologies, and user environments is fundamental for successful channel differentiation and targeted market strategies.
Market entry and growth tactics require adaptation to region-specific regulatory frameworks, infrastructure limits, and local payer engagement processes.

Tariff Impact on the Anti-Obesity Drugs Market

Anticipated changes in tariffs and trade rules are likely to raise production costs and disrupt distribution channels, particularly impacting manufacturers of injectables reliant on specialized cold-chain logistics. Higher duties on pharmaceutical ingredients and device components may test supply continuity, encouraging manufacturers to diversify their supplier base, explore nearshoring, and create inventory buffers to manage risk. Provider procurement teams could prioritize local or vertically integrated supply chains to minimize tariff exposure. Added customs checks and compliance requirements threaten to stretch clinical supply chain timelines. A collaborative, cross-functional approach to mitigation is critical to protect access and ensure supply stability.

Methodology & Data Sources

This report is based on a comprehensive mixed-methods research approach, combining structured interviews with clinicians, procurement professionals, patient representatives, and device engineers alongside robust secondary research. Data sources include peer-reviewed journals, regulatory filings, and technical specifications, with outcomes confirmed through expert panel validation and analytical triangulation.

Why This Report Matters

Offers actionable market intelligence to guide product development, scale-up decisions, and channel strategies tailored to current and emerging market dynamics.
Supports planning for resilient supply chains, payer negotiations, and digital integration across different segments and geographies.
Arms decision-makers with insights needed for effective collaboration, evidence generation, and competitive market posture.

Conclusion

The anti-obesity drugs landscape is entering a period of significant transformation and operational challenges. Companies that align technology, care pathways, and commercial models with patient-centric principles and agile supply strategies will support sustainable market access and long-term growth opportunity.

Additional Product Information:

Purchase of this report includes 1 year online access with quarterly updates.
This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025

8. Anti-Obesity Drugs Market, by Product Type

8.1. Glp-1 Agonists
8.2. Naltrexone Bupropion
8.3. Orlistat
8.4. Phentermine Topiramate
8.5. Sglt2 Inhibitors

9. Anti-Obesity Drugs Market, by Dosage Form

9.1. Capsules
9.2. Injectables
9.2.1. Prefilled Pens
9.2.2. Vials
9.3. Tablets

10. Anti-Obesity Drugs Market, by Route Of Administration

10.1. Injectable
10.1.1. Autoinjector
10.1.2. Prefilled Pen
10.1.3. Vial
10.2. Nasal
10.3. Oral

11. Anti-Obesity Drugs Market, by End User

11.1. Clinics
11.2. Homecare Settings
11.3. Hospitals

12. Anti-Obesity Drugs Market, by Region

12.1. Americas
12.1.1. North America
12.1.2. Latin America
12.2. Europe, Middle East & Africa
12.2.1. Europe
12.2.2. Middle East
12.2.3. Africa
12.3. Asia-Pacific

13. Anti-Obesity Drugs Market, by Group

13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO

14. Anti-Obesity Drugs Market, by Country

14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea

15. United States Anti-Obesity Drugs Market
16. China Anti-Obesity Drugs Market

17. Competitive Landscape

17.1. Market Concentration Analysis, 2025
17.1.1. Concentration Ratio (CR)
17.1.2. Herfindahl Hirschman Index (HHI)
17.2. Recent Developments & Impact Analysis, 2025
17.3. Product Portfolio Analysis, 2025
17.4. Benchmarking Analysis, 2025
17.5. Alvogen Iceland EHF
17.6. Amgen Inc
17.7. Arena Pharmaceuticals Inc
17.8. AstraZeneca plc
17.9. Bayer AG
17.10. Boehringer Ingelheim International GmbH
17.11. Currax Pharmaceuticals LLC
17.12. Eli Lilly and Company
17.13. F Hoffmann La Roche Ltd
17.14. GlaxoSmithKline plc
17.15. Innovent Biologics Inc
17.16. LG Chem Ltd
17.17. Merck and Co Inc
17.18. Novo Nordisk A S
17.19. Pfizer Inc
17.20. Rhythm Pharmaceuticals Inc
17.21. Takeda Pharmaceutical Company Limited
17.22. Teva Pharmaceutical Industries Ltd
17.23. VIVUS LLC
17.24. Zydus Lifesciences Ltd

List of Figures

FIGURE 1. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL ANTI-OBESITY DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL ANTI-OBESITY DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 12. CHINA ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

List of Tables

TABLE 1. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY GLP-1 AGONISTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY GLP-1 AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY GLP-1 AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY NALTREXONE BUPROPION, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY NALTREXONE BUPROPION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY NALTREXONE BUPROPION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ORLISTAT, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ORLISTAT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ORLISTAT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PHENTERMINE TOPIRAMATE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PHENTERMINE TOPIRAMATE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PHENTERMINE TOPIRAMATE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PREFILLED PENS, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PREFILLED PENS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PREFILLED PENS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY VIALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY VIALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY VIALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY AUTOINJECTOR, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY AUTOINJECTOR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY AUTOINJECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PREFILLED PEN, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PREFILLED PEN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PREFILLED PEN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY VIAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY VIAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY VIAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY NASAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY NASAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY NASAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 67. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 68. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 69. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 70. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 71. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 72. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 73. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 75. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 76. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 77. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 78. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 79. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 80. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 81. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 82. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 83. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 84. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 85. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 86. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 94. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 95. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 96. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 97. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 98. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 99. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 100. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 101. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 102. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 103. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 104. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 105. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 106. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 107. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 108. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 109. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 110. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 111. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 112. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 113. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 114. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 115. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 116. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 117. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 118. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 119. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 120. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 121. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 123. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 124. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 125. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 126. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 127. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 128. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 129. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 130. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 131. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 132. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 133. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 134. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 135. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 136. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 137. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 138. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 139. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 140. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 141. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 142. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 143. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 144. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 145. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 146. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 147. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 148. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 149. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 150. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 151. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 152. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 153. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 154. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 155. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 156. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 157. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 158. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 159. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 160. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 161. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 162. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 163. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 164. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 165. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 166. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 167. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 168. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 169. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 170. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 171. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 172. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 173. CHINA ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 174. CHINA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 175. CHINA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 176. CHINA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 177. CHINA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 178. CHINA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 179. CHINA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Anti-Obesity Drugs market report include:

Alvogen Iceland EHF
Amgen Inc
Arena Pharmaceuticals Inc
AstraZeneca plc
Bayer AG
Boehringer Ingelheim International GmbH
Currax Pharmaceuticals LLC
Eli Lilly and Company
F Hoffmann La Roche Ltd
GlaxoSmithKline plc
Innovent Biologics Inc
LG Chem Ltd
Merck and Co Inc
Novo Nordisk A S
Pfizer Inc
Rhythm Pharmaceuticals Inc
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd
VIVUS LLC
Zydus Lifesciences Ltd

Table Information

Report Attribute	Details
No. of Pages	189
Published	January 2026
Forecast Period	2026 - 2032
Estimated Market Value ( USD ) in 2026	$ 4.67 Billion
Forecasted Market Value ( USD ) by 2032	$ 7.07 Billion
Compound Annual Growth Rate	7.0%
Regions Covered	Global
No. of Companies Mentioned	21

License	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access	This is a single user license, allowing one user access to the product.	€3501EUR$3,939USD£3,033GBP
1 - 5 USER LICENSE PDF, Excel and Online Access	This is a 1-5 user license, allowing up to five users have access to the product.	€3777EUR$4,249USD£3,272GBP
SITE LICENSE PDF, Excel and Online Access	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5119EUR$5,759USD£4,434GBP
ENTERPRISE LICENSE PDF, Excel and Online Access	This is an enterprise license, allowing all employees within your organization access to the product.	€6194EUR$6,969USD£5,366GBP

Market Snapshot: Anti-Obesity Drugs Market

Scope & Segmentation

Key Takeaways

Tariff Impact on the Anti-Obesity Drugs Market

Methodology & Data Sources

Why This Report Matters

Conclusion

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

Anti-Obesity Drugs Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Molecule, Active Compound Used, Mechanism of Action, Type of Agonist, Action Pathway, Route of Administration, Geographical Regions, Sales Forecast and Key Players

North America Anti-Obesity Drugs Market Size, Share & Industry Trends Analysis Report By Drug Type, By Mechanism of Action, By Route Of Administration (Oral Route and Subcutaneous Route), By Distribution Channel, By Country and Growth Forecast, 2023-2029

Asia Pacific Anti-Obesity Drugs Market Report and Forecast 2024-2032

Anti-Obesity Drugs - Global Strategic Business Report

Anti-Obesity Drugs Market Report and Forecast 2025-2034